Evidence map›Paper›PMID 39155697›Full record

ArticleJournal of surgical oncology2024

Oncogenic pathway signatures predict the risk of progression and recurrence in well-differentiated pancreatic neuroendocrine tumors.

Michael A Mederos, Colin M Court, Benjamin J Dipardo, Joseph R Pisegna, David W Dawson, O Joe Hines, Timothy R Donahue, Thomas G Graeber, Mark D Girgis, James S Tomlinson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Michael A MederosDepartment of Surgery, University of California Los Angeles, Los Angeles, California, USA.
Colin M CourtMays Cancer Center, University of Texas Health San Antonio, San Antonio, Texas, USA.
Benjamin J DipardoDepartment of Surgery, University of California Los Angeles, Los Angeles, California, USA.
Joseph R PisegnaDepartment of Molecular, Cellular, and Integrative Physiology, University of California Los Angeles, Los Angeles, California, USA.
David W DawsonDepartment of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California, USA.
O Joe HinesDepartment of Surgery, University of California Los Angeles, Los Angeles, California, USA.
Timothy R DonahueDepartment of Surgery, University of California Los Angeles, Los Angeles, California, USA.
Thomas G GraeberDepartment of Molecular, Cellular, and Integrative Physiology, University of California Los Angeles, Los Angeles, California, USA.
Mark D GirgisDepartment of Surgery, University of California Los Angeles, Los Angeles, California, USA.ORCID http://orcid.org/0000-0002-8085-4422
James S TomlinsonDepartment of Surgery, University of California Los Angeles, Los Angeles, California, USA.

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Robert Damoiseaux · 1985 to 2026
$134.5M
UCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REITER, ROBERT E · 2002 to 2023
$42.6M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
TARGETED COMBINATORIAL TREATMENT OF BRAF MELANOMASP01CA168585 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RIBAS, ANTONI · 2013 to 2017
$8.4M
Mammalian models for integrated metabolic and molecular profiling of malignant gliomaR01CA227089 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GRAEBER, THOMAS G, NATHANSON, DAVID A. · 2018 to 2022
$2.7M
Targeting Genomic Instability in Lethal Neuroendocrine Prostate CancerR01CA222877 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GRAEBER, THOMAS G, WITTE, OWEN N. · 2018 to 2022
$2.6M
Hirshberg Foundation for Pancreatic ResearchNCI/NIH P01CA168585NCI/NIH P50CA092131NCI/NIH R01CA222877NCI/NIH R01CA227089NCI NIH HHS P01 CA168585NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA092131NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA222877NCI NIH HHS R01 CA227089W.M. Keck Foundation
6 · The paper itself

Abstract

backgroundPancreatic neuroendocrine tumors (pNETs) are genomically diverse tumors. The management of newly diagnosed well-differentiated pNETs is limited by a lack of sensitivity of existing biomarkers for prognostication. Our goal was to investigate the potential utility of genetic markers as a predictor of progression-free survival (PFS) and recurrence-free survival (RFS).

methodsWhole-exome sequencing of resected well-differentiated, low and intermediate-grade (G1 and G2) pNETs and normal adjacent tissue from patients who underwent resection from 2005 to 2015 was performed. Genetic alterations were classified using pan-genomic and oncogenic pathway classifications. Additional samples with genetic and clinicopathologic data available were obtained from the publicly available International Cancer Genome Consortium (ICGC) database and included in the analysis. The prognostic relevance of these genomic signatures on PFS and RFS was analyzed.

resultsThirty-one patients who underwent resection for pNET were identified. Genomic analysis of mutational, copy number, cytogenetic, and complex phenomena revealed similar patterns to prior studies of pNETs with relatively few somatic gene mutations but numerous instances of copy number changes. Analysis of genomic and clinicopathologic outcomes using the combined data from our study as well as the ICGC pNET cohort (n = 124 patients) revealed that the recurrent pattern of whole chromosome loss (RPCL) and metastatic disease were independently associated with disease progression. When evaluating patients with local disease at the time of resection, RPCL and alterations in the TGFβ oncogenic pathway were independently associated with the risk of recurrence.

conclusionsWell-differentiated pNETs are genomically diverse tumors. Pathway signatures may be prognostic for predicting disease progression and recurrence.

Indexed as

Biomarkers, TumorDisease ProgressionNeoplasm Recurrence, LocalNeuroendocrine TumorsPancreatic NeoplasmsAdultAgedExome SequencingFemaleFollow-Up StudiesHumansMaleMiddle AgedMutationPrognosisSurvival RateBiomarkers, Tumorgenomic biomarkerpancreatic neuroendocrine tumorprognosisrecurrencewhole‐exome sequencing

Identifiers

PMID39155697
PMCPMC11654900

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.